ATE227986T1 - Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 - Google Patents
Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2Info
- Publication number
- ATE227986T1 ATE227986T1 AT98930032T AT98930032T ATE227986T1 AT E227986 T1 ATE227986 T1 AT E227986T1 AT 98930032 T AT98930032 T AT 98930032T AT 98930032 T AT98930032 T AT 98930032T AT E227986 T1 ATE227986 T1 AT E227986T1
- Authority
- AT
- Austria
- Prior art keywords
- ucp
- regulation
- obesity
- diabetes mellitus
- metabolic syndrome
- Prior art date
Links
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 title abstract 4
- 101710112393 Mitochondrial uncoupling protein 2 Proteins 0.000 title abstract 4
- 230000033228 biological regulation Effects 0.000 title abstract 3
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- 238000010187 selection method Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 6
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 4
- 208000008589 Obesity Diseases 0.000 abstract 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 4
- 235000020824 obesity Nutrition 0.000 abstract 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702457A SE9702457D0 (sv) | 1997-06-26 | 1997-06-26 | Screening |
| PCT/SE1998/001232 WO1999000123A1 (en) | 1997-06-26 | 1998-06-24 | Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE227986T1 true ATE227986T1 (de) | 2002-12-15 |
Family
ID=20407529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98930032T ATE227986T1 (de) | 1997-06-26 | 1998-06-24 | Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1001758B1 (de) |
| JP (1) | JP2002508770A (de) |
| AT (1) | ATE227986T1 (de) |
| AU (1) | AU744134B2 (de) |
| CA (1) | CA2295747A1 (de) |
| DE (1) | DE69809558T2 (de) |
| NZ (1) | NZ502112A (de) |
| SE (1) | SE9702457D0 (de) |
| WO (1) | WO1999000123A1 (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023568A2 (en) * | 1998-10-06 | 2000-04-27 | Albert Einstein College Of Medicine Of Yeshiva University | Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells |
| WO2001035096A2 (en) * | 1999-11-10 | 2001-05-17 | Mitokor | Diseases associated with altered mitochondrial function |
| US6365796B1 (en) * | 2000-02-16 | 2002-04-02 | Beth Israel Deaconess Medical Center | Transgenic UCP2 knockout mouse and use thereof |
| CA2414033A1 (en) * | 2000-06-22 | 2001-12-27 | Genentech, Inc. | Control of metabolism with compositions of the human 2-oxoglutarate carrier |
| ES2177404B1 (es) * | 2000-07-07 | 2004-09-16 | Consejo Superior De Investigaciones Cientificas | Procedimiento para la determinacion de la actividad de las proteinas desacoplantes (ucps) mediante la monitorizacion del consumo de nad (p) h. |
| WO2003002732A1 (en) * | 2001-06-27 | 2003-01-09 | Biovitrum Ab | Citrate lyase poly peptides |
| AU2003214048A1 (en) * | 2002-01-25 | 2003-09-02 | Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | Proteins involved in the regulation of energy homeostasis and organelle metabolism |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| FR2853911B1 (fr) * | 2003-04-17 | 2005-07-08 | Merck Sante Sas | Gene induit par l'insuline, comme cible therapeutique dans le diabete |
| WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
| JPWO2005028647A1 (ja) * | 2003-09-22 | 2006-11-30 | 国立大学法人京都大学 | 核酸プローブ、核酸チップ、標的核酸検出方法、薬剤スクリーニング方法、標的核酸検出装置及び遺伝子診断方法 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| EP1784390A2 (de) | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituierte benzokondensierte heterozyklen |
| EP1892241B1 (de) | 2005-05-30 | 2016-03-30 | Msd K.K. | Neues piperidinderivat |
| EP1916239A4 (de) | 2005-08-10 | 2009-10-21 | Banyu Pharma Co Ltd | Pyridolverbindung |
| US7875633B2 (en) | 2005-08-24 | 2011-01-25 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
| WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| RU2008119687A (ru) | 2005-10-21 | 2009-11-27 | Новартис АГ (CH) | Комбинации органических соединений |
| AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
| RU2428423C2 (ru) | 2005-11-10 | 2011-09-10 | Баниу Фармасьютикал Ко., Лтд. | Азазамещенные спиропроизводные |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| EP2072519A4 (de) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | Diarylketiminderivat |
| JP4814774B2 (ja) | 2006-12-06 | 2011-11-16 | 花王株式会社 | 肥満調節剤の評価方法 |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5099856B2 (ja) | 2007-11-26 | 2012-12-19 | 独立行政法人科学技術振興機構 | 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法 |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| CA2717384A1 (en) | 2008-03-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Zusammensetzungen zur behandlung von magen-darm-störungen |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| EP3883930A1 (de) | 2018-11-20 | 2021-09-29 | Tes Pharma S.r.l. | Inhibitoren der alpha-amino-beta-carboxymuconsäure-semialdehyddecarboxylase |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4623619A (en) * | 1982-03-03 | 1986-11-18 | Nordisk Insulinlaboratorium | Method for the determination of liability in human individuals to develop atherosclerosis |
| FR2557137B1 (fr) * | 1983-12-21 | 1986-05-23 | Centre Nat Rech Scient | Sonde d'adnc reconnaissant l'arnm de la proteine decouplante des mitochondries du tissu adipeux brun des mammiferes, procede de preparation et application |
| DE793646T1 (de) * | 1994-11-23 | 1999-12-30 | Pharmacia & Upjohn Co., Kalamazoo | Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus |
| FR2733513B1 (fr) * | 1995-04-25 | 1997-07-18 | Centre Nat Rech Scient | Lignees immortalisees de cellules issues du tissu adipeux humain, leur procede de preparation et leurs applications |
| US5783408A (en) * | 1995-06-07 | 1998-07-21 | Hamilton; Bradford S. | Method for screening potential anti-obesity agents |
| US6566089B1 (en) * | 1996-09-04 | 2003-05-20 | Tularik Inc. | Cell-based drug screens for regulators of gene expression |
| WO1998031396A1 (en) * | 1997-01-15 | 1998-07-23 | Duke University | Respiration uncoupling protein |
-
1997
- 1997-06-26 SE SE9702457A patent/SE9702457D0/xx unknown
-
1998
- 1998-06-24 DE DE69809558T patent/DE69809558T2/de not_active Expired - Fee Related
- 1998-06-24 WO PCT/SE1998/001232 patent/WO1999000123A1/en not_active Ceased
- 1998-06-24 EP EP98930032A patent/EP1001758B1/de not_active Expired - Lifetime
- 1998-06-24 JP JP50549299A patent/JP2002508770A/ja active Pending
- 1998-06-24 AT AT98930032T patent/ATE227986T1/de not_active IP Right Cessation
- 1998-06-24 CA CA002295747A patent/CA2295747A1/en not_active Abandoned
- 1998-06-24 NZ NZ502112A patent/NZ502112A/en unknown
- 1998-06-24 AU AU79513/98A patent/AU744134B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SE9702457D0 (sv) | 1997-06-26 |
| AU744134B2 (en) | 2002-02-14 |
| CA2295747A1 (en) | 1999-01-07 |
| WO1999000123A1 (en) | 1999-01-07 |
| DE69809558D1 (de) | 2003-01-02 |
| AU7951398A (en) | 1999-01-19 |
| JP2002508770A (ja) | 2002-03-19 |
| NZ502112A (en) | 2002-02-01 |
| DE69809558T2 (de) | 2003-04-10 |
| EP1001758B1 (de) | 2002-11-20 |
| EP1001758A1 (de) | 2000-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69809558D1 (de) | Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 | |
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| BR9906796A (pt) | Método para a administração de análogos de insulina monoméricos | |
| WO2004110375A3 (en) | Combination therapy for the treatment of diabetes | |
| BR0210167A (pt) | Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto | |
| WO2004073614A3 (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
| ATE432289T1 (de) | Glp-1 und behandlungsmethode für diabetes | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| EA200400589A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| EA200500782A1 (ru) | Лечение геморрагического шока | |
| BR9814280A (pt) | Arilpiperazinas que apresentam atividade noreceptor 1a de serotonina | |
| ATE552031T1 (de) | Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz | |
| DE69531004D1 (de) | p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES | |
| ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
| BR0011928A (pt) | Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética | |
| ATE198278T1 (de) | Verwendung von sulodexid und von arzneimitteln, die dieses enthalten, zur behandlung der diabetischen nephropathie | |
| ATE199829T1 (de) | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon | |
| SE9601397D0 (sv) | Use of growth hormone | |
| ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| Kapur et al. | Spinal cord stimulation for relief of abdominal pain in two patients with familial Mediterranean fever | |
| BR9812531A (pt) | Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica | |
| DE69822810D1 (de) | Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x | |
| WO2002007765A3 (en) | REGULATORS OF PPARδ(β) AND THEIR USE IN THE TREATMENT OF OBESITY AND INSULIN RESISTANCE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |